COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus

Digestive and Liver Disease

Volumn 39, Issue 4, 2007, Pages 305-311

  Villanacci, V ^a   Rossi, E ^a   Zambelli, C ^a   Galletti, A ^a   Cestari, R ^b   Missale, G ^b   Casa, D Della ^b   Bassotti, G ^c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Digestive Endoscopy Unit   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Barrett's esophagus; Carcinoma; CDC2; CDX2; COX 2; Dysplasia

Indexed keywords

CYCLIN DEPENDENT KINASE 1; CYCLOOXYGENASE 2; TRANSCRIPTION FACTOR CDX2;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CELL NUCLEUS; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENDOSCOPIC BIOPSY; ENDOSCOPIC MUCOSAL RESECTION; EPITHELIUM DYSPLASIA; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; MEDICAL ASSESSMENT; PATHOPHYSIOLOGY; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; BIOLOGICAL MARKERS; CDC2 PROTEIN KINASE; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE 2; ESOPHAGEAL NEOPLASMS; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS;

EID: 33947272999     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.01.011     Document Type: Article

References (29)

1. Goldblum J.R. Barrett's esophagus and Barrett's-related dysplasia. Mod Pathol 16 (2003) 316-324
2. Koppert L.B., Wijnhoven B.P., van Dekken H., Tilanus H.W., and Dinjens W.N. The molecular biology of esophageal adenocarcinoma. J Surg Oncol 92 (2005) 169-190
3. Krishnadath K.K., Reid B.J., and Wang K.K. Biomarkers in Barrett esophagus. Mayo Clin Proc 76 (2001) 438-446
4. Buttar N.S., and Wang K.K. Mechanisms of disease: carcinogenesis in Barrett's esophagus. Nat Clin Pract Gastroenterol Hepatol 1 (2004) 106-112
5. Morris C.D., Armstrong G.R., Bigley G., Green H., and Attwood S.E. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 96 (2001) 990-996
6. Buskens C.J., Van Rees B.P., Sivula A., Reitsma J.B., Haglund C., Bosma P.J., et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 122 (2002) 1800-1807
7. Lagorce C., Paraf F., Vidaud D., Couvelard A., Wendum D., Martin A., et al. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma. Histopathology 42 (2003) 457-465
8. Kaur B.S., Khamnehei N., Iravani M., Namburu S.S., Lin O., and Triadafilopoulos G. Rofecoxib inhibits cyclooxygenase-2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 123 (2002) 60-67
9. Tuynman J.B., Buskens C.J., Kemper K., ten Kate F.J., Offerhaus G.J., Richel D.J., et al. Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann Surg 242 (2005) 840-850
10. Almeida R., Silva E., Santos-Silva F., Silberg D.G., Wang J., De Bolos C., et al. Expression of intestine-specific transcription factors, CDX1 e CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol 199 (2003) 36-40
11. Silberg D.G., Swain G.P., Suh E.R., and Traber P.G. CDX1 and CDX2 expression during intestinal development. Gastroenterology 119 (2000) 961-971
12. Phillips R.W., Frierson H.R., and Moskaluk C.A. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 27 (2003) 1442-1447
13. Groisman G.M., Amar M., and Meir A. Expression of the intestinal marker CDX2 in the columnar-lined esophagus with and without intestinal (Barrett's) Metaplasia. Mod Pathol 17 (2004) 1282-1288
14. Draetta G., Brizuela L., Moran B., and Beach D. Regulation of the vertebrate cell cycle by the cdc2 protein kinase. Cold Spring Harb Symp Quant Biol 53 (1988) 195-201
15. Nozoe T., Takahashi I., Baba H., and Maehara Y. Relationship between intracellular localization of p34cdc2 protein and differentiation of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 131 (2005) 179-183
16. Hansel D.E., Dhara S., Huang R.C., Ashfaq R., Deasel M., Shimada Y., et al. CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target. Am J Surg Pathol 29 (2005) 390-399
17. Riddel R.H., Goldman H., Ransohoff D.F., Appelman H.D., Fenoglio C.M., Haggitt R.C., et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 14 (1983) 931-968
18. Geboes K., and Van Eyken P. The diagnosis of dysplasia and malignancy in Barrett's esophagus. Histopathology 37 (2000) 99-107
19. Montgomery E., Bronner M.P., Goldblum J.R., Greenson J.K., Haber M.M., Hart J., et al. Reproducibility of the diagnosis in Barrett esophagus: a reaffirmation. Hum Pathol 32 (2001) 368-378
20. Hamilton S.R., and Aaltonen L.A. WHO pathology and genetics: tumors of digestive system (2000), IARC Press, Lyon
21. Lim H.Y., Joo H.J., Choi J.H., Yi J.W., Yang M.S., Cho D.Y., et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 6 (2000) 519-525
22. Moons L.M., Bax D.A., Kuipers E.J., Van Dekken H., Haringsma J., Van Vliet A.H., et al. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol 57 (2004) 1063-1068
23. Kandil H.M., Tanner G., Smalley W., Halter S., Radhika A., and Dubois R.N. Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci 46 (2001) 785-789
24. Abdalla S.I., Lao-Sirieix P., Novelli M.R., Lovat L.B., Sanderson I.R., and Fitzgerald R.C. Gastrin-induced Ciclooxygenase-2 expression in Barrett's carcinogenesis. Clin Cancer Res 10 (2004) 4784-4792
25. Shirvani V., Ouatu-Iscar R., Kaur B., Omary M.B., and Triadafilopoulos G. Cyclooxygenase-2 expression in Barrett's esophagus and adenocarcinoma - Ex vivo induction by bile salts and acid exposure. Gastroenterology 118 (2000) 487-496
26. Eda A., Osawa H., Satoh K., Yanaka I., Kihira K., Ishino Y., et al. Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. J Gastroenterol 38 (2003) 14-22
27. Phillips R.W., and Wong R.K. Barrett's esophagus. Natural history, incidence, etiology, and complications. Gastroenterol Clin North Am 20 (1991) 791-816
28. Kaimaktchiev V., Terracciano L., Tornillo L., Spitchin H., Stoios D., Bundi M., et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol 17 (2004) 1392-1399
29. Rugge M., Ingravallo G., Farinati F., Russo V.M., Zaninotto G., and Alvisi V. CDX2 homeotic gene expression in gastric noninvasive neoplasia. Am J Surg Pathol 28 (2004) 834-835